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Cardiothoracic surgeries are complex procedures during which the patient
cardiovascular physiology is constantly changing due to various factors. Physiological
changes begin with the induction of anesthesia, whose effects remain active into
the postoperative period. Depending on the surgery, patients may require the use
of cardiopulmonary bypass and cardioplegia, both of which affect postoperative
physiology such as cardiac index and vascular resistance. Complications may arise
due to adverse reactions to the surgery, causing hemodynamic instability. In response,
fluid resuscitation and/or vasoactive agents with varying effects may be used in the
intraoperative or postoperative periods to improve patient hemodynamics. These factors
have important implications for lumped-parameter computational models which aim
to assist surgical planning and medical device evaluation. Patient-specific models are
typically tuned based on patient clinical data which may be asynchronously acquired
through invasive techniques such as catheterization, during which the patient may be
under the effects of drugs such as anesthesia. Due to the limited clinical data available
and the inability to foresee short-term physiological regulation, models often retain
preoperative parameters for postoperative predictions; however, without accounting
for the physiologic changes that may occur during surgical procedures, the accuracy
of these predictive models remains limited. Understanding and incorporating the
effects of these factors in cardiovascular models will improve the model fidelity and
predictive capabilities.
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INTRODUCTION
There are several factors that can cause significant changes in the cardiovascular physiology
during cardiothoracic surgeries and patient management. For instance, prior to surgery, patients
undergo the induction of anesthesia and remain under its influence in the intraoperative and
early postoperative periods. Surgeries may also require cardiopulmonary bypass and cardioplegia
to isolate and depress the heart. Complications may arise due to unforeseen circumstances, and
patients may be treated with fluids and vasoactive agents to improve their hemodynamic state.
The implications of these factors on the fidelity of computational cardiovascular models
are far-reaching. Current cardiovascular models, in particular lumped-parameter models, seek
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to simulate patient physiology to aid in clinical decision making;
these models are constructed using primarily pre-operative
clinical data and do not consider the events which may affect
patient physiology during surgery (1, 2). Therefore, the aim of
this work is to summarize the primary factors affecting the state
of physiology during the acquisition of clinical data and in the
postoperative environment, and discuss their implications on
lumped-parameter cardiovascular modeling.
PHYSIOLOGY UNDER ANESTHESIA
Several anesthetic combinations are used in surgery, each with
significant and unique effects on the cardiovascular system.
Currently, there is no universally accepted combination of
anesthetic agents for cardiac surgeries. The choice of drugs is
determined by the pathophysiologic state of the patient and
the knowledge of the anesthesiologist. For initial hypnosis,
inhalational agents or intravenous agents are typically used, while
narcotics and muscle relaxants are used during periods of high
stimulation such as intubation. The management of anesthesia is
important in maintaining stable hemodynamics and an adequate
blood supply to body tissues.
Volatile inhalational agents typically cause dose-dependent
myocardial depression. Nitrous oxide is an inhalational
anesthetic sometimes used in the pre-bypass period due to
its rapid onset and elimination. It can be used to increase
pulmonary pressures, and, to a lesser extent, depress contractility
(although this is usually offset by the release of catecholamines)
(3). However, it is not used during bypass due to its high blood
solubility and propensity to expand air bubbles, increasing the
risk of air emboli. Isoflurane is one of the most widely used
volatile anesthetics due to its minimal cardiac effects as well as
its ability to reduce cerebral metabolic oxygen requirements. It
causes arterial blood pressure to decline, but preserves cardiac
output (CO) due to an active carotid baroreceptor reflex which
decreases systemic vascular resistance (SVR) and afterload
(3, 4). Desflurane is in many respects similar to isoflurane,
however, in increased concentrations, it may cause temporary
sympathetic activity (5). Sevoflurane is the newest of the
volatile anesthetics. It is able to reduce myocardial damage
and preserve ventricular function. Similar to isoflurane, it also
depresses cerebral metabolic requirements, protecting the brain
from ischemia. Most volatile agents directly alter the body’s
natural temperature regulation mechanisms as well, causing a
diminished threshold for cold responses such as shivering and
vasoconstriction, which when paired with vasodilatory effects,
commonly induces hypothermia (6). The cardiovascular effects
of inhalational anesthetics are summarized in Table 1.
Other types of anesthetic agents include intravenous agents
such as Barbiturates, Ketamine, and Propofol. Barbiturates
are occasionally used in cardiac surgery, acting to depress
the metabolic demands of the brain and providing protection
against ischemia. They are usually safe only in hemodynamically
stable patients, making their use rather limited. Their use is
associated with a decrease in blood pressure and an increase in
heart rate (HR) due to vasodilation and decreased contractility
(7). Ketamine is a hypnotic used to block neurotransmission
to the brain. It has been shown to increase HR and mean
arterial pressure (MAP) and is sometimes used in patients with
depressed cardiovascular function such as those with congenital
heart disease (8). Propofol is another hypnotic becoming a
popular choice for anesthesiologists due to its fast metabolism,
enabling the rapid emergence from sedation and early extubation
(9). Propofol causes a dose-dependent decrease in HR and
blood pressure due to decreases in contractility and peripheral
resistance (10).
Opioids and Muscle relaxants are other types of anesthetic
drugs, which may be administered to control pain and muscle
movement, respectively.Muscle relaxants such as succinylcholine
may result in abnormal heart beats, however both opioids and
muscle relaxants cause very minimal changes to CO and blood
pressure when compared to volatile or intravenous agents (11).
Although the current line of anesthetic drugs has been
used for some time, there is an active search for agents with
fewer adverse effects. One candidate is the inhalational use of
Xenon. Other inert gases such as Argon have been found to
have anesthetic qualities, but Xenon possesses the most potent
anesthetic capabilities of the inert gasses. In an animal trial using
Xenon on guinea pigs, Stowe et al. demonstrated that it had
no mechanical, electrical, or metabolic effects on isolated guinea
pig hearts (12). In a study comparing the effects of Xenon with
propofol, Xenon sedation after cardiac surgery was found to be
as safe as Propofol, while also offering an additional advantage of
a rapid awaking time (13). Factors currently limiting the use of
Xenon in cardiac surgery are its cost and the requirements for a
unique delivery system.
FACTORS INFLUENCING POSTOPERATIVE
PHYSIOLOGY
Cardiopulmonary Bypass and Cardioplegic
Solution
Some operations such as valve replacement, congenital heart
defect surgery, and coronary artery bypass graft (CABG) surgery
require the use of a CPB machine to take over the function
of the patient’s heart and lungs, enabling the stopping of the
heart. The heart is most often stopped by a cardioplegic (CP)
solution decreasing the resting potential of the heart. This stops
the heart, reduces its metabolism and oxygen demand, and allows
the cardiac surgeon to work on a bloodless and motionless heart
during the procedure.
The CPB machine operation and the CP solution directly
impact postoperative states. Davidson et al. found that increased
doses of CP were associated with greater degrees of increased
left anterior descending coronary artery flow after congenital
cardiac surgery (14). Ameta-analysis of 5,879 patients comparing
warm and cold cardioplegia found that warm cardioplegia
was associated with a higher postoperative cardiac index (CI)
but suggests other possible influences such as intermittent vs.
continuous, antegrade vs. retrograde, and composition of CP
(15). CPB perfusion temperature is another factor which has
been found to influence postoperative patient conditions. Tönz
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TABLE 1 | Cardiovascular effects of inhalational anesthetics (3).
Drug Blood pressure Heart rate Systemic
vascular
resistance
Cardiac output Cerebral flow Renal flow Hepatic flow
Nitrous oxide 0 0 0 0 + −− –
Halothane −− – 0 – ++ −− −−
Enflurane −− + – −− + −− −−
Isoflurane −− + −− 0 + −− –
Desflurane −− 0 or + −− 0 or – + – –
Sevoflurane – 0 – – + – –
et al. found that systemic vascular resistance at 3 hours and
9 hours after CPB was higher for patients who underwent
surgery with hypothermic CPB as compared to normothermic
CPB (16).
Postoperative Complications
Typically, there is an increased oxygen demand as patients are
weaned off CPB and anesthesia. There are similar increases
in oxygen metabolism in both CABG and off-pump CABG
patients, likely due to inflammatory responses to surgical
trauma (17). The surgical stress response, whose magnitude and
duration are proportional to surgical injury, increases activity
of the sympathetic nervous system and causes a release of
hormones which promote catabolism, increasing the overall
metabolism (18).
A common complication following cardiac surgery is low
cardiac output syndrome (LCOS). This is typically due to
diminished heart pump function, leading to reduced oxygen
delivery (DO2) and tissue hypoxia. It is characterized by a CI
<2.0 L/min/m2 and a systolic blood pressure <90 mmhg (19).
Physical signs of LCOS include tissue hypoperfusion resulting in
cold and clammy skin, confusion, and elevated lactate level. Many
other complications arise from LCOS such as acute renal failure,
atrial fibrillation, and pulmonary complications. Common
underlying mechanisms behind LCOS are left ventricular (LV)
systolic dysfunction, LV diastolic function, and right ventricular
(RV) dysfunction.
LV systolic dysfunction is commonly a result of
myocyte necrosis due to impaired coronary circulation and
ischemia/reperfusion injury. The ventricle’s impaired response
to preload (reduced ejection fraction) causes a decrease in
CO and DO2 and increase in left atrial pressure (LAP). LV
diastolic dysfunction is the inability of the left ventricle to accept
an adequate volume of blood, despite a normal preload. This
may be caused by severe tachycardia, decreased myocardial
compliance, or impaired ventricular relaxation. Diastolic
dysfunction is a common occurrence in cardiac patients in the
postoperative period after CABG due to increased chamber
stiffness (20). Right ventricular (RV) dysfunction, which may be
developed due to intraoperative RV ischemia and infarction, is
characterized by increased RV preload, increased RV afterload,
right coronary artery perfusion impairment, and decreased RV
contractility (19).
Another common postoperative condition occurring in 5–
15% of patients following cardiac surgery involving CPB is
vasoplegia, characterized by low systemic vascular resistance and
high or normal CO (21). A lack of vascular tone and decreases
in blood flow result in inadequate driving perfusion pressures
to the tissue, reducing oxygen delivery and causing subsequent
“shock.” Temperature and duration of CPB, volume of infused
CP, preoperative treatment with angiotensin-converting-enzyme
inhibitors, and reduced left ventricular function were found to be
risk factors for vasoplegia (21).
Other complications which can lead to shock include
hemorrhage and sepsis. Hemorrhagic shock is a type of
hypovolemic shock produced by a rapid loss of intravascular
blood volume. Rapid decreases in blood volume typically
lead to decreases in CO and DO2 due to inadequate left
ventricular preload. However, there is little change in VO2
due to a redistribution of blood flow to tissues with greater
metabolic needs caused by the lowering of regional vascular
resistance. As the volume of blood loss increases, blood pressure
continues to drop, and heart rate increases in an compensatory
effort to increase CO (22). However, when blood loss exceeds
approximately 30% of blood volume, the sympathetic nervous
system becomes inhibited, resulting in a normal or decreased
heart rate and a drop in arterial blood pressure (23). In this
sympatho-inhibitory phase, DO2 decreases to the point where
VO2 can no longer be maintained.
On the other hand, sepsis is defined as the presence of
systemic inflammatory response syndrome (SIRS) symptoms
with suspected or proven infection. SIRS is a stress response
which occurs as a result of injury such as that caused by surgical
trauma or cardiopulmonary bypass, whose symptoms include
abnormalities in body temperature, heart rate, respiratory rate,
and white cell count (24). The initial SIRS response may lead
to immunosuppression, making patients more susceptible to
infection and the development of sepsis (25). Some of the
diagnostic criteria for sepsis are: HR >90 beats/min. or >2
standard deviations (SD) above normal for age, systemic blood
pressure (SBP)<90mmHg,MAP<70mmHg, SBP decrease>40
mmHg in adults, or < 2 SD below normal for age (26). Sepsis
can lead to a low cardiac output, causing tissue hypotension and
hypoperfusion. Although the occurrence of sepsis is rare after
cardiac surgery, those who develop the condition experience a
high mortality (25).
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POST-OPERATIVE MANAGEMENT
Fluid Resuscitation
Fluid resuscitation is often the first step in treating patients
with low levels of tissue perfusion. The primary reason for
treating patients with intravenous fluids is to increase stroke
volume through an increase in preload. Following the Frank-
Starling principle, increasing LV preload will increase LV stroke
volume until an optimal preload is reached, after which the
stroke volume will remain relatively constant. However, just
50% of hemodynamically unstable patients respond positively
to fluids (volume responsive) (27). For those who are not
volume responsive, fluid resuscitation can lead to increased
complications. Dynamic tests of volume responsiveness do exist,
allowing clinicians to determine the degree to which a patient
may be fluid-responsive (28)
Current Vasoactive Agents
If fluid resuscitation fails to bring the patient’s postoperative
hemodynamics into a stable range, vasoactive agents are
often employed. The most common vasoactive agents are
catecholamines. These agents induce sympathetic responses of
the autonomic nervous system, triggering the “fight or flight”
response. Catecholamines induce cardiovascular effects primarily
through α1, β1, β2, and dopaminergic receptors. The activation
of α1 adrenergic receptors results in vascular smooth muscle
contraction and subsequent increase in SVR. β1 adrenergic
receptor activation causes enhanced myocardial contractility
through calcium ion channel activation and increased HR.
β2 adrenergic stimulation results in an increased calcium ion
uptake and vasodilation in skeletal muscle vessels. Lastly,
dopaminergic receptor stimulation causes renal and mesenteric
vasodilation (29).
Epinephrine is a naturally occurring catecholamine and
adrenergic agonist of both α and β receptors. It is a potent
vasoconstrictor with inotropic and chronotropic effects. High
and prolonged doses can cause cardiac toxicity by damaging
arterial walls (29). Although it may be used as an inotropic agent
in LCOS, its effects are largely unpredictable (19).
Another catecholamine is norepinephrine, which is primarily
an α adrenergic agent, with a modest effect on β adrenergic
receptors. It can generate significant vasoconstriction, exhibiting
inotropic and chronotropic effects to a much lesser degree.
Norepinephrine is generally used for treatment of hypotensive
and normovolemic patients experiencing shock (30). Prolonged
norepinephrine use, similar to epinephrine, may cause a toxic
effect on cardiac myocytes (29).
Dopamine is a naturally occurring catecholamine that acts
on dopaminergic and adrenergic receptors to cause a range
of hemodynamic effects. At low doses, β receptor responses
dominate, resulting in increased contractility and HR with a
modest increase in SVR. However, with increasing doses, α1
adrenergic vasoconstriction effects dominate (29). Side effects of
dopamine include tachycardia and arrhythmia (31).
Dobutamine is a synthetic catecholamine that is primarily
β1 adrenergic. It enhances ventricular contraction with only
slight vasodilation effects. It is a potent inotrope that causes
mild increases in chronotropic effects, and consequently causes a
dose dependent increase in CO. However, it increases myocardial
oxygen demand, limiting its clinical use due to risk of ischemia,
and may cause ventricular arrhythmias (29, 32).
Another class of vasoactive agents are phosphodiesterase
(PDE) inhibitors. PDE inhibitors increase intracellular cyclic
adenosine monophosphate which produces inotropic effects as
well as systemic and pulmonary vasodilatory effects. Milrinone is
the most commonly used PDE inhibitor. Unlike catecholamines,
it does not cause increases in myocardial VO2 or HR, and
is commonly used as a secondary agent when hemodynamic
improvement cannot be accomplished with catecholamines (29).
Vasopressin, also known as “antidiuretic hormone,” is stored
in the pituitary gland and released after hypotension or pain
stimulus, and leads to vasoconstriction, consequently increasing
SVR (29). It is not associated with the adverse effects of
adrenergic agents, and enables an increase in MAP without
adversely affecting CO (33). Another agent used to increase
SVR is methylene blue. Methylene blue competes directly
with Nitric Oxide (NO) in its ability to activate the enzyme
guanylate, which produces cyclic guanosine monophosphate
(responsible for smooth muscle relaxation). This reduces the
responsiveness of vessels to vasodilators such as NO (34). Both
vasopressin andmethylene blue can be used to reverse vasoplegia,
however methylene blue is recommended as a strategy of
last resort (33).
Levosimendan is a relatively new drug that acts as a calcium-
sensitizing agent. It increases myofilament sensitivity to calcium,
leading to an increase in myocardial contractility without a
significant increase in VO2. It also causes the opening of
potassium channels on vascular smooth muscle, resulting in
vasodilation, sometimes leading to undesired hypotension (29,
32). The cardiovascular effects of the vasoactive agents described
above are summarized in Table 2.
Emerging Agents
Although the current repertoire of vasoactive agents is vast,
they are not without disadvantages and side effects. The
search for new vasoactive agents with capabilities of improving
and stabilizing hemodynamics is ongoing, but there are a
few recent developments that are promising. These agents
will give more control to anesthesiologists, perfusionists, and
nurses who are responsible for monitoring and maintaining
patient hemodynamics.
One new agent being investigated is istaroxime. It increases
sarcoplasmic reticular calcium adenosine triphosphatase and
inhibits sodium potassium adenosine triphosphatase activity.
This results in an increase in calcium concentration during
systole (increasing inotropy) and a rapid decrease in calcium
during diastole (increasing lusitropy). These combined effects
produce increased systolic and diastolic performance without
increasing myocardial oxygen consumption, offering a major
advantage over existing inotropes (35).
Another group of vasoactive agents with promising
capabilities are cardiac myosin activators. In a trial of patients
with stable heart failure and left systolic function, the agent
omecamtiv mecarbil demonstrated an ability to increase the
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TABLE 2 | Common vasoactive drugs and their effects. Adapted with permission (32, 33).
Mechanism of action Cardiac Peripheral Vasculature
Drug α1 β1 β2 Dopaminergic Heart rate Contractility Vasoconstriction Vasodilation
Epinephrine –/+* ++ + 0 ++++ ++++ ++++ +++
Norepinephrine ++ ++ – 0 + ++ ++++ 0
Dopamine –/+* –/++ * –/+* ++ +/++ * +/++ * 0/++ * +/0*
Dobutamine – ++ + 0 ++ +++/++++ * 0 ++
Milrinone Phosphodiesterase inhibitors + +++ 0 ++
Vasopressin V1 receptor agonist 0 0 ++++ 0
Methylene blue Monoamine oxidase inhibitor 0 0 ++++ 0
Levosimendan Calcium-sensitizer + +++ 0 ++
*The ‘/’ denotes differences between effects at low vs. high dosages. Typical dosages can be found in Morozowich and Ramakrishna (33) and Hollenberg (32).
duration of left ventricular systole, increasing the ejection
fraction (36). This increase improves myocardial efficiency
by enhancing ventricular contraction without an increase in
myocardial oxygen consumption. Although these agents have not
been observed in the immediate intensive care unit environment,
they do offer a potential avenue of use in patients with depressed
CO after surgery.
IMPLICATIONS FOR
LUMPED-PARAMETER MODELING
Assessing the efficacy of cardiothoracic surgeries in practice is
difficult, relying on past surgeries for guidance, but advances in
the field of computational cardiovascular modeling have opened
the door to the evaluation of surgeries and medical devices
in a virtual setting. One approach to simulate cardiovascular
physiology and hemodynamics is by implementing a zero-
dimensional lumped-parameter network (LPN). The LPN
models the circulatory system as a network of electrical circuit
elements, which accounts for the effects of friction, inertia,
and vessel compliance with electrical analogs of resistance,
inductance, and capacitance, respectively. This gives rise to a
system of ordinary differential equations whose solution provides
values of hemodynamic variables such as blood pressure and flow
rate in different locations of the circulation.
LPN has been used to predict hemodynamic responses under
varying circumstances such as surgical intervention, disease
conditions, and ventricular assist device support (37). For
example, bi-directional Glenn and hemi-Fontan operations for
a patient requiring congenital heart defect correction surgery
were compared by coupling 3D models of altered geometries
with a pre-operative LPN model (1). By using a similar
approach, another study developed a framework to study the
influence of graft shape in coronary artery bypass graft surgery
on local hemodynamics and global circulatory dynamics (2).
Furthermore, LPN models have been used for the design
and evaluation of cardiovascular assist devices where in vivo
studies are impractical (38). LPN can also be implemented in a
hardware-in-the-loop approach through coupling with a physical
experiment; this approach simultaneously captures physical
interactions not easily simulated and provides feedback from
the physiologic simulation to the experiment (39). Researchers
are also developing interactive training modules using LPN
models that enable the simulation of cardiovascular diseases and
therapies (40).
When constructing a patient-specific LPN physiology
model, it is necessary to tune the model to accurately reflect
the patient’s cardiovascular system. This is accomplished
using available clinical data acquired through methods such
as cardiac catheterization and magnetic resonance imaging.
Standard-of-care patient data acquired prior to surgery are
often obtained at different times and when the physiological
state of the patient varies due to the influences of factors
such as anesthesia. Furthermore, once they have been tuned,
LPN parameters are often assumed unchanged in simulations
predicting postoperative hemodynamics (1, 2). However,
as discussed, the patient physiology changes during the
preoperative, intraoperative, and postoperative management
periods for several reasons. To advance the state of the art
in cardiovascular modeling and improve model prediction
accuracy, advanced methods should account for the effects of
these factors in simulating postoperative outcomes.
CONCLUSION
As discussed, patient cardiovascular physiology in cardiothoracic
surgery changes due to many factors: induction of anesthesia,
use of cardiopulmonary bypass and cardioplegia, responses
to surgical trauma, fluid resuscitation, and administration of
vasoactive agents. Without accounting for these factors in
lumped-parameter cardiovascular models, the ability of models
to predict postoperative hemodynamics will remain limited.
The goal of this paper is to provide a summary describing the
primary sources of physiologic changes during surgery that
affect hemodynamics as the first step in guiding future model
improvement; only after recognizing these sources can we know
where to direct focus to incorporate their effects quantitatively
into models. For example, transient dissipation of anesthesia
may be accounted for by integrating pharmacodynamic
models to reflect a period of postoperative recovery. As fluid
resuscitation and vasoactive agents are available for intentional
hemodynamic management, implementing their effects in
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models may encourage their use in developing surgical strategies,
accounting for post-operative management flexibility. With an
increasing volume of available data and advances in modeling
algorithms, incorporating the complex nature of these factors
in cardiovascular models is an area ripe for exploration
and pursuit.
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